In the present study an attempt has been made to formulate and evaluate a sustained release periodontal film of Sparfloxacin with biodegradable, cost effective polymer Chitosan. The objective of the study was to formulate intra-pocket periodontal films, which could be easily placed into the periodontal pocket, and thus be capable of delivering therapeutic concentrations of drug. Sparfloxacin is an antibiotic, showing wide spectrum antibacterial activity against a number of periodontal pathogens. Hence Sparfloxacin is selected as model for site specific delivery, i.e., into periodontal pocket for the treatment of periodontitis. In the present investigation Chitosan films containing Sparfloxacin were prepared by solution casting method using acetic acid. The copolymers HPMC K4M, Sodium CMC and Eudragit RL 100 in the concentrations of 10%, 20% and 30% w/w of Chitosan were added into the polymeric solution. Propylene glycol was used as plasticizer. FT-IR and UV spectroscopic methods revealed no interaction between Sparfloxacin and polymers. The drug loaded films were evaluated for their thickness, weight variation, content uniformity, tensile strength, percent elongation, percentage moisture loss, surface pH, folding endurance, in-vitro drug release studies, in -vitro antibacterial activity and stability studies. Periodontal films showed initial burst release of drug on 1 st day and then the release was sustained for a period of 8 days. In -vitro antibacterial activity was carried out on staphylococcus aureus and the antibacterial activity was retained for 96 hours. In -vitro release from periodontal films was fit to kinetic models to reveal drug release kinetics.

Popular cancer therapies face extreme disadvantages, including multimedicament tolerance and non-target impact. These issues will lead to poorer patient conformity and poor levels of survival. Successful medical therapies for cancer patients are desperately required. Nano-particulate structures with a pluronic base represent revolutionary platforms for anti-cancer agent provision. These structures provide great potential for the advancement of cancer therapy due to their pharmacological properties and sufficient physicochemical characteristics. This review aims to offer a more detailed description of the pluronic drug delivery mechani sms that are currently available and explains pluronic as a medicinal polymer. Hydrophobic payload formulations and updated, targeted distribution mechanisms are explained based on pluronic formulations. This analysis offers a rundown of the current situation art related to the theranostic application of polymer micelles targeting the microenvironment of cancer cells. Some guidelines for the future scope and possible opportunities are also been addressed. Search criteria: Primary sources such as Medline a principal component of PubMed, an online, searchable, and biomedical and life science research literature database has been used. It brings readers to almost any area of interest with research and journal articles. One of the internet resources of importance to get scientific publications is specialized scientific search engines known as Google Scholar a database of research material that can be searched for. I have used the online electronic access portal of Elsevier, such as Science Direct to its publications. Scopus is the biggest abstract and peer-reviewed literature database for scientific journals, books, and conference work. Keywords like Cancer, Pluronic, Nanoparticles, Chemotherapy, Cancer, Theranostic, Targeted, Micelles, and Core-shell are crucial as they notify search engines of the content of the site. Range of years: 1992-2020.

No abstract

An innovative RP-HPLC technique was devised to simultaneously quantify thymoquinone (TQ) and capecitabine (CAP) in newly designed polymeric nanoparticles. A unique chromatographic approach was created, optimized and validated using Design-Expert® (design of experiment) in compliance with ICH requirements. A 24 factorial design examined the influence of variables on method responses. The method found linear between 0.25 and 16 μg/mL, with an R2 value of 0.999. The detection and quantification limits for CAP were 0.05 and 0.16 μg/mL, respectively, and 0.12 and 0.38 μg/mL for TQ, respectively, and 97–100% recovery in plain drug solution and 100–102% in nanoformulation were achieved. A purposeful modification examined by analysis of variance revealed that the experimental model was significant (P = 0.0001). The total drug content in nanoformulation was 8.68 mg, and the entrapment efficiency was 84.79%. Based on the findings, it is possible to infer that the use of the Quality by Design methodology resulted in the development of a more accurate technique capable of producing consistent, dependable, high-quality data and precise in quantifying CAP and TQ in bulk and nanoparticulate systems.